PA
CRVS icon

Parallel Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Parallel Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20
Closed -$106 – 3537
2024
Q3 		$106 Hold
20
– – ﹤0.01% 3334
2024
Q2 		$36 Hold
20
– – ﹤0.01% 3278
2024
Q1 		$36 Hold
20
– – ﹤0.01% 3239
2023
Q4 		$35 Hold
20
– – ﹤0.01% 3265
2023
Q3 		$29 Hold
20
– – ﹤0.01% 3317
2023
Q2 		$46 Hold
20
– – ﹤0.01% 3314
2023
Q1 		$18 Hold
20
– – ﹤0.01% 3392
2022
Q4 		$17 Hold
20
– – ﹤0.01% 3320
2022
Q3 		$0 Hold
20
– – ﹤0.01% 3198
2022
Q2 		$0 Hold
20
– – ﹤0.01% 3051
2022
Q1 		$0 Hold
20
– – ﹤0.01% 3016
2021
Q4 		$0 Hold
20
– – ﹤0.01% 3118
2021
Q3 		$0 Hold
20
– – ﹤0.01% 3100
2021
Q2 		$0 Buy
+20
New +$55 ﹤0.01% 2952

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Parallel Advisors's CRVS Position: Q4 2024 in Review

Parallel Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q4 2024, closing a stake of 20 shares — an estimated $106 sold.

Parallel Advisors first reported a position in CRVS in Q2 2021 and held it in 14 quarters. The position peaked at $106 in Q3 2024. 85 funds tracked by Wall St. Rank hold CRVS as of Q4 2024.

  • Parallel Advisors reported no remaining Corvus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Parallel Advisors sold 20 Corvus Pharmaceuticals shares in Q4 2024, an estimated $106.
  • Parallel Advisors first reported a position in Corvus Pharmaceuticals in Q2 2021 and held it in 14 quarters.
  • Parallel Advisors's Corvus Pharmaceuticals position peaked at $106 in Q3 2024.
  • 85 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2024.

Based on Parallel Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.